Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring
Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Log in
Top

09-12-2022 | GLP-1 agonists | Ask the expert | Article

Initiating GLP-1 receptor agonists: Managing side effects

print
PRINT
insite
SEARCH

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them (7:12).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

View or download the titration guidance 

Download the high resolution version

About the expert

Nicola Milne is a Primary Care Diabetes Specialist Nurse, working across primary care networks (PCNs) and within the wider community to give support and education to all health care professionals (HCPs) in the delivery of optimal and holistic care to adults living with type 2 diabetes.


Full biography

print
PRINT

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video

Related content

04-28-2020 | GLP-1 agonists | News

Early findings suggest route to GLP-1 receptor agonism with less gastrointestinal discomfort

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

02-07-2022 | Dulaglutide | At a glance | Article

A quick guide to the AWARD trials

02-11-2021 | Semaglutide | At a glance | Article

A quick guide to the STEP trials
Image Credits